Measured by returns in 2013, the top 10 funds had only three from large houses; nimble strategy could be a factor.
IT, pharma and FMCG stocks are the top performers in 2013.
After relentlessly selling shares for most of 2013, India's equity mutual fund managers have turned buyers in the fag-end of the year.
The 46-year-old chairman of the Aditya Birla Group has made at least 28 acquisitions since he took the reins of the group 18 years ago.
The move comes less than two months after the Union Budget clarified that returns from pass through certificates were tax-exempt.
Many fund managers at domestic institutions had cut their exposure to Infosys shares ahead of the March quarter earnings.
The state's tax department had collected Rs 64 crore (Rs 640 million) from ACC, against which the company moved the Himachal Pradesh High Court.
Investors redeem units worth Rs 2,000 crore in October.
Unitech, a New Delhi-based real estate developer, has said various bills related to land and real estate sector may impact the sector's growth if various stakeholders' interests are not taken care of.
With the prevailing uncertainty in equity markets and an indefinite postponement of hopes of any recovery, retail investors accessing stock markets through equity mutual fund schemes are wriggling out fast.
They say enough correction already; monthly net investment hits 24-month high.
Not many takers for debt funds with longer maturity.
Data shows of the 385 companies, which had announced their latest shareholding, fund houses cut their stake in about 200.
Foreign fund houses outperformed their domestic peers in terms of garnering assets in 2010-11.
An ETF is an investment fund traded on stock exchanges, much like stocks. An ETF holds assets such as stocks, commodities or bonds.
The growth will happen in the asset management market, as the Indian population is richer and economy would continue to grow.
India's leading private airport developers, GMR and GVK groups, are planning to bid for the modernisation of Ngurah Rai International Airport in Bali, Indonesia. Both are currently undertaking feasibility studies and preparing to participate in the tender process, sources said.
Antacid Digene and pain drug Brufen have been among the top in their categories in India for decades. But not their manufacturer, Abbott.
But the newer entrants prove nimbler than the slowing pioneers.
In 2000, it was projected as the next big thing to happen in healthcare, for its potential to replicate the outsourcing success stories in information technology and business process outsourcing.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances